Abstract 2068P
Background
Sexual dysfunction is a frequently seen late effect in patients treated for testicular germ cell tumour (TGCT). Therefore, monitoring of sexual dysfunction is essential. The Utrecht Symptom Diary (USD) helps monitoring cancer symptoms, but items regarding sexuality are missing. Adding these symptoms may provide a better tailored tool, enhance monitoring of late effects on sexuality, and might help to address this topic. Therefore, the aim of this study was to explore perspectives and concerns on late effects regarding sexuality among adolescents and young adults (AYAs) being treated for TGCT to adapt the USD to make it suitable for follow-up care for these patients.
Methods
Individual, semi-structured interviews were conducted with thirteen AYAs from one centre of expertise for TGCT in the Netherlands. Patients were purposively sampled and using maximum variation. Data was analysed using Braun and Clark’s thematic analysis.
Results
Interviews revealed seven overarching themes which interact and overlap: fulfilment to have children, rediscover sexuality, insecurity about sexual performance, acceptance of physical change, loss of masculinity, burden on relationship, and need to talk about sexuality. Concerns related to the fulfilment to have children seems to play a major role.
Conclusions
Results help to better understand these men’s thoughts and experiences related to late effects regarding sexuality and gives healthcare professionals the opportunity to act on these topics by discussing it in the consulting room. Partner involvement seems beneficial.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2028TiP - Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) + ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3
Presenter: Julien Mazieres
Session: Poster session 06
2029TiP - Phase I study of ABBV-706, an anti-SEZ6 antibody-drug conjugate, alone or in combination in adults with advanced solid tumors
Presenter: Sreenivasa Chandana
Session: Poster session 06
2035P - Routine biomarker monitoring does not replace comprehensive clinical assessment in the detection of immunotherapy induced myocarditis
Presenter: Alexandra Johnson
Session: Poster session 06
2036P - Prevalence and risk evaluation of cardiovascular disease among newly diagnosed prostate cancer population in China
Presenter: Weiyu Zhang
Session: Poster session 06
2037P - Prehabilitation as a strategy to improve postoperative outcomes in frail cancer patients undergoing elective surgery: A systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Poster session 06
2039P - Primary endpoints of confirmatory randomized controlled trials for older patients with cancer: A scoping review
Presenter: Tomonori Mizutani
Session: Poster session 06
2041P - The prevalence of hematologic adverse events (HAEs) and myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) in patients (pts) with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitor (PARPi), with or without a germline BRCA pathogenic variant
Presenter: Carmine Valenza
Session: Poster session 06
2042P - Improving breast cancer outcomes for indigenous women
Presenter: Vita Christie
Session: Poster session 06
2043P - Can Charlson Comorbidity Index (CCI) and Clinical Frailty Scale (CFS) assessments predict survival in octogenarians with colorectal cancer?
Presenter: Neda Nikolic
Session: Poster session 06
2044P - Bloodstream infections (BSI) in cancer patients: Epidemiology, antibiotic therapy and risk factors related to mortality
Presenter: Carlos López Jiménez
Session: Poster session 06